View in EDS

Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Saved in:
Bibliographic Details
Title: Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Authors: Sridhar, Vikas S.1,2 (AUTHOR), Kugathasan, Luxcia1,2,3 (AUTHOR), Lytvyn, Yuliya2,3 (AUTHOR), Deng, Yangqing4 (AUTHOR), Liu, Hongyan2,3 (AUTHOR), Lovblom, Leif Erik4,5 (AUTHOR), Tse, Josephine3 (AUTHOR), Nardone, Massimo3 (AUTHOR), Floras, John S.6 (AUTHOR), Osuntokun, Tosin6 (AUTHOR), Tobushi, Tomoyuki6 (AUTHOR), Lam, Ruthabella C.Y.3 (AUTHOR), Lam, Brian2 (AUTHOR), Stevens, Jasper7 (AUTHOR), Burger, Dylan8 (AUTHOR), Touw, Daan J.7 (AUTHOR), Heerspink, Hiddo J.L.7 (AUTHOR), Lovshin, Julie A.2,9,10 (AUTHOR), Perkins, Bruce A.2,9,11 (AUTHOR), Cherney, David Z.I.2,3 (AUTHOR) david.cherney@uhn.ca
Source: Hypertension (0194911X). Feb2026, Vol. 83 Issue 2, pe25955-e25955.
Database: SPORTDiscus with Full Text
Description
ISSN:0194911X
DOI:10.1161/HYPERTENSIONAHA.125.25955